Post_template - Page 5 of 10

BIO Asia Partnering Forum, April 26-27, 2023, Singapore, SG

Delighted to announce that OncoOne’s CEO, Randolf Kerschbaumer, will be attending BIO Asia Partnering Forum ASIABIO, held in Singapore April 26-27! Join us as he presents our latest developments in our oxMIF targeted pipeline for cancer and inflammation.

OncoOne Presents Preclinical Data Update from oxMIF-targeting Pipeline including ON203 and PreTarg-it ® ON-05 at the 2023 AACR Annual Meeting

PDF – Next-generation anti-oxMIF antibody ON203 demonstrates anti-tumor effects through tumor cell death and modulation of the immunosuppressive tumor microenvironment in human tumoroids isolated from colorectal adenocarcinoma patients.– First preclinical data from OncoOne’s PreTarg-it® platform show significant tumor regression and survival benefit in models of

AACR Annual Meeting, April 14-19, 2023, Orlando, FL, US

Meet with our CTO Alexander Schinagl and CBO Brent Meadows at our two posters entitled: Poster #2974 “Targeting the oxidized form of macrophage migration inhibitory factor (oxMIF) with antibody ON203 activates the tumor microenvironment” and Poster #585 “Pretargeted radioimmunotherapy with a novel anti-oxMIF/HSG bispecific antibody

OncoOne Newsletter Q1/2023

“OncoOne has had a successful start to 2023, with the lead oxMIF mAb for solid tumors, ON203, being featured in the American Association for Cancer Research’s journal Molecular Cancer Therapeutics. The summary of ON203’s design and preclinical experiments has been published online in conjunction with

Promotion of Friedmund Bachmann to Vice President CMC

We are delighted to announce Friedmund Bachmann’s well-deserved promotion to the role of Vice President CMC at OncoOne, effective April 1, 2023! With a remarkable career spanning renowned companies such as Baxter, Baxalta, Shire, and Takeda, Friedmund has gathered a wealth of experience and held

Promotion of Christine Landlinder-Schubert, PhD to Vice President Preclinical and Translational R&D.

We are thrilled to announce the well-deserved promotion of Christine Landlinger-Schubert to the role of Vice President Preclinical and Translational R&D at OncoOne, effective April 1, 2023! With nearly 15 years of experience in the biotech industry, Christine has consistently showcased her exceptional skills and

Immuno UK, March 28-29, 2023, London, UK

Participating in the Immuno 2023 in London from March 28-29th? Be sure to attend the presentation by our CSO, Michael Thiele entitled “Targeting oxMIF in autoimmune diseases” on March 28 from 11:10 – 11:35 am GMT. Participants will have the opportunity to learn more about

BIO-EUROPE Spring, 2023 March 20–22, 2023, Basel, CH

Meet our CEO, Randolf Kerschbaumer, at the BIO-Europe Spring 2023 to learn more about OncoOne’s novel therapies for the treatment of solid tumors and chronic inflammatory diseases. Reserve a spot using the partneringONE® tool to speak with our management team about the recent developments of

Maroua Ferhat, PhD was promoted to Senior Scientist

We are thrilled to announce that Maroua Ferhat, PhD has been awarded the promotion to Senior Scientist effective March 1, 2023 Maroua has been with the company for a year and a half and has progressively taken on more responsibility in our biology group, where

18th Annual Congress of the European Crohn’s and Colitis Organisation, March 1-4, 2023, Copenhagen, DK

Meet with our Scientist Maroua Ferhat for the ECCO 2023 held in Copenhagen from March 1 – 4, where she will lead a poster presentation on our oxMIF-targeting monoclonal antibody, ON104 which shows efficacy in two distinct preclinical models of experimental colitis.